Bausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and ...

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, ...

AND JESS, YOU SAY THIS COULD BE A GAME CHANGER. YOU KNOW, IT REALLY CAN. ABOUT 3 MILLION AMERICANS HAVE GLAUCOMA AND THIS NEW TREATMENT IS BASICALLY AN IMPLANTABLE DRUG FOR THE EYE. AND DOCTORS SAY IT ...

Smith, MD, of Glaucoma Associates of Texas, in Dallas, sat down with the Eye Care Network to reflect on how glaucoma care ...

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years. Neil Minkoff, MD: Where do we see glaucoma therapy going in the next 24 to 36 months, due to ...

Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

Please provide your email address to receive an email when new articles are posted on . Glaucoma-related ocular surface disease is a significant and often underdiagnosed ocular comorbidity that can ...

Glaucoma causes vision loss by damaging the optic nerve. This leads to loss of peripheral vision and eventually blindness. The damage to the optic nerve is multifactorial, but increased ocular ...

Please provide your email address to receive an email when new articles are posted on . “Glaucoma medication is associated with changes in meibomian glands morphology, including decreased acinar area, ...

A retrospective analysis of national health statistics in Scotland from 1994 to 2004. The Scottish morbidity record was used to collect information on all episodes of trabeculectomy. Data on number of ...

Glaucoma is a term that refers to a group of eye diseases that cause damage to the optic nerve. This nerve damage can lead to vision loss and blindness. Since glaucoma is asymptomatic in its early ...